XML 52 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Liquidity (Narrative) (Details)
12 Months Ended
Jan. 10, 2023
USD ($)
$ / shares
Mar. 31, 2022
USD ($)
shares
Feb. 09, 2022
USD ($)
tranche
$ / shares
shares
Oct. 28, 2021
USD ($)
$ / shares
shares
Jan. 26, 2021
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
$ / shares
Liquidity, management evaluation           The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern.  
Cash and cash equivalents | $           $ 14,852,000 $ 10,288,000
Proceeds from issuance of private placement | $     $ 45,000,000        
Common stock, par value (in dollars per share) | $ / shares       $ 0.01   $ 0.01 $ 0.01
Innoviva Strategic Opportunities LLC [Member] | Secured term loan              
Aggregate amount | $ $ 30,000,000            
Interest rate (as a percent) 8.00%            
Common stock, par value (in dollars per share) | $ / shares $ 0.01            
Discount on share price for conversion 15.00%            
Price per share | $ / shares $ 1.52            
Innoviva Strategic Opportunities LLC [Member] | Secured term loan | Maximum [Member]              
Discount on share price for conversion 15.00%            
Securities Purchase Agreement [Member]              
Proceeds from equity offerings, gross | $       $ 7,000,000.0      
Shares Issued, Price Per Share | $ / shares       $ 3.30      
Securities Purchase Agreement [Member] | Cystic Fibrosis Foundation [Member]              
Stock Issued During Period, Shares, New Issues       909,091      
Securities Purchase Agreement [Member] | Innoviva Strategic Opportunities LLC [Member]              
Securities purchase agreement maximum gross proceeds | $     $ 45,000,000        
Number of tranches | tranche     2        
Stock Issued During Period, Shares, New Issues     9,000,000 1,212,122      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     4,500,000        
Exercise price of warrants | $ / shares     $ 5.00        
Proceeds from issuance of common stock and warrants | $     $ 18,100,000        
Securities Purchase Agreement [Member] | Common Stock Subject to Mandatory Redemption [Member]              
Shares Issued, Price Per Share | $ / shares         $ 3.25    
Stock Issued During Period, Shares, New Issues         6,153,847    
Exercise price of warrants | $ / shares         $ 3.25    
Securities Purchase Agreement [Member] | Warrants and Rights Subject to Mandatory Redemption [Member] | Maximum [Member]              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights         6,153,847    
Securities Purchase Agreement First Tranche [Member] | Innoviva Strategic Opportunities LLC [Member]              
Stock Issued During Period, Shares, New Issues     3,614,792        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     1,807,396        
Proceeds from issuance of common stock and warrants | $     $ 18,100,000        
Securities Purchase Agreement Second Tranche [Member] | Innoviva Strategic Opportunities LLC [Member]              
Stock Issued During Period, Shares, New Issues   5,385,208          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   2,692,604          
Proceeds from issuance of common stock and warrants | $   $ 26,900,000